Attorney Docket No.: ISPH-0533
Inventors: Monia et al.
Serial No.: 09/757,100
Filing Date: January 9, 2001
Page 2

The following listing of claims will replace all prior versions and listings of claims in this application.

Listing of Claims:

Claims 1-44 (canceled)

Claim 45 (currently amended): A method of inhibiting tumor cell invasion, reducing the viability of melanoma cells or inhibiting melanoma cell growth in an animal comprising administering to an animal *ex vivo* a therapeutically or prophylactically effective amount of an antisense compound 8 to 30 nucleobases in length targeted to nucleobases 1 through 20, nucleobases 78 through 97, nucleobases 101 through 120, nucleobases 150 through 169, nucleobases 183 through 202, nucleobases 206 through 225, or nucleobases 211 through 230 of a 5'-untranslated region, nucleobases 229 through 248 of a start codon region, ~~a coding region,~~ nucleobases 3383 through 3402 of a stop codon region, or nucleobases 3444 through 3463, nucleobases 3510 through 3529, nucleobases 3590 through 3609, nucleobases 3658 through 3677, nucleobases 3680 through 3699, or nucleobases 3738 through 3757 of a 3'-untranslated region of a nucleic acid molecule encoding focal adhesion kinase of SEQ ID NO: 1.

E1

Claim 46 (previously added): The method of claim 45 wherein the antisense compound is an antisense oligonucleotide.

Claim 47 (currently amended): ~~The~~ A method of inhibiting tumor cell invasion, reducing the viability of melanoma cells or inhibiting melanoma cell growth in an animal comprising administering to an animal a therapeutically or prophylactically effective amount of an antisense compound 8 to 30 nucleobases in length ~~of claim 46~~ wherein the antisense ~~oligonucleotide~~ compound comprises SEQ ID NO: 18.

E1

Claim 48 (previously added): The method of claim 46 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

Claim 49 (previously added): The method of claim 48 wherein the modified internucleoside linkage is a phosphorothioate linkage.

Claim 50 (previously added): The method of claim 46 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Claim 51 (previously added): The method of claim 50 wherein the modified sugar moiety is a 2'-o-methoxyethyl moiety.

Claim 52 (previously added): The method of claim 46 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Claim 53 (previously added): The method of claim 52 wherein the modified nucleobase is a 5-methylcytosine.

Claim 54 (previously added): The method of claim 46 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Claim 55 (previously amended): The method of claim 45 wherein said antisense compound is administered in combination with a therapeutically or prophylactically effective amount of 5-fluorouracil.